|
KR20100080812A
|
|
Methods of synthesis for therapeuthic anti-hiv peptides
|
|
CN101678125A
|
|
Novel formulations for delivery of antiviral peptide therapeutics
|
|
US2007259879A1
|
|
Piperazine and piperidine biaryl derivatives
|
|
NZ570300A
|
|
HIV fusion inhibitor peptides with improved biological properties
|
|
US2007202127A1
|
|
Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
|
|
WO2005089796A1
|
|
Site-specific chemical modification of hiv gp41-derived peptides
|
|
WO2005067960A1
|
|
HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
|
|
WO2004043913A2
|
|
Hetero-substituted benzimidazole compounds and antiviral uses thereof
|
|
WO2004029074A2
|
|
Hiv-derived hr1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
|
|
CN1812799A
|
|
Pharmaceutical composition for improved administration of HIV gp41-derived peptides,And its use in therapy
|
|
US7556813B2
|
|
Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
|
|
US7045552B2
|
|
Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
|
|
US7030150B2
|
|
Benzimidazole compounds and antiviral uses thereof
|
|
US6623741B1
|
|
Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
|
|
US6750008B1
|
|
Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
|
|
US6656906B1
|
|
Hybrid polypeptides with enhanced pharmacokinetic properties
|
|
US6541020B1
|
|
Methods and compositions for administration of therapeutic reagents
|
|
US6469136B1
|
|
Methods and composition for peptide synthesis
|
|
WO9948513A1
|
|
Methods and compositions for peptide synthesis
|
|
US6258782B1
|
|
Hybrid polypeptides with enhanced pharmacokinetic properties
|
